Acetyl Sulfisoxazole
The metabolism of Lenvatinib can be decreased when combined with Acetyl sulfisoxazole.
Acetyldigitoxin
Acetyldigitoxin may decrease the cardiotoxic activities of Lenvatinib.
Albuterol
Salbutamol may increase the QTc-prolonging activities of Lenvatinib.
Advertisement
Alfuzosin
Alfuzosin may increase the QTc-prolonging activities of Lenvatinib.
Amantadine
Amantadine may increase the QTc-prolonging activities of Lenvatinib.
Amiodarone
Lenvatinib may increase the QTc-prolonging activities of Amiodarone.
Advertisement
Amitriptyline
Amitriptyline may increase the QTc-prolonging activities of Lenvatinib.
Amoxapine
Amoxapine may increase the QTc-prolonging activities of Lenvatinib.
Anagrelide
Lenvatinib may increase the QTc-prolonging activities of Anagrelide.
Advertisement
Ancestim
The risk or severity of cytotoxicity can be increased when Ancestim is combined with Lenvatinib.
Apalutamide
The serum concentration of Lenvatinib can be decreased when it is combined with Apalutamide.
Apomorphine
Apomorphine may increase the QTc-prolonging activities of Lenvatinib.
Aprepitant
The serum concentration of Lenvatinib can be increased when it is combined with Aprepitant.
Arformoterol
Arformoterol may increase the QTc-prolonging activities of Lenvatinib.
Aripiprazole
Aripiprazole may increase the QTc-prolonging activities of Lenvatinib.
Arsenic Trioxide
Lenvatinib may increase the QTc-prolonging activities of Arsenic trioxide.
Artemether
Lenvatinib may increase the QTc-prolonging activities of Artemether.
Asenapine
Lenvatinib may increase the QTc-prolonging activities of Asenapine.
Atazanavir
The metabolism of Lenvatinib can be decreased when combined with Atazanavir.
Atomoxetine
The metabolism of Lenvatinib can be decreased when combined with Atomoxetine.
Azithromycin
Azithromycin may increase the QTc-prolonging activities of Lenvatinib.
Bedaquiline
Bedaquiline may increase the QTc-prolonging activities of Lenvatinib.
Bevacizumab
Bevacizumab may increase the cardiotoxic activities of Lenvatinib.
Bevacizumab-Awwb
Bevacizumab may increase the cardiotoxic activities of Lenvatinib.
Boceprevir
The metabolism of Lenvatinib can be decreased when combined with Boceprevir.
Bortezomib
The metabolism of Lenvatinib can be decreased when combined with Bortezomib.
Bosentan
The serum concentration of Lenvatinib can be decreased when it is combined with Bosentan.
Bosentan Anhydrous
The serum concentration of Lenvatinib can be decreased when it is combined with Bosentan.
Buserelin
Buserelin may increase the QTc-prolonging activities of Lenvatinib.
Cabazitaxel
The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Lenvatinib.
Carbamazepine
The metabolism of Lenvatinib can be increased when combined with Carbamazepine.
Ceritinib
The serum concentration of Lenvatinib can be increased when it is combined with Ceritinib.
Chloroquine
Chloroquine may increase the QTc-prolonging activities of Lenvatinib.
Chlorpromazine
Chlorpromazine may increase the QTc-prolonging activities of Lenvatinib.
Ciprofloxacin
Ciprofloxacin may increase the QTc-prolonging activities of Lenvatinib.
Cisapride
Lenvatinib may increase the QTc-prolonging activities of Cisapride.
Citalopram
Lenvatinib may increase the QTc-prolonging activities of Citalopram.
Clarithromycin
The metabolism of Lenvatinib can be decreased when combined with Clarithromycin.
Clemastine
The metabolism of Lenvatinib can be decreased when combined with Clemastine.
Clomipramine
Clomipramine may increase the QTc-prolonging activities of Lenvatinib.
Clotrimazole
The metabolism of Lenvatinib can be decreased when combined with Clotrimazole.
Clozapine
Clozapine may increase the QTc-prolonging activities of Lenvatinib.
Cobicistat
The metabolism of Lenvatinib can be decreased when combined with Cobicistat.
Conivaptan
The serum concentration of Conivaptan can be increased when it is combined with Lenvatinib.
Crizotinib
Crizotinib may increase the QTc-prolonging activities of Lenvatinib.
Curcumin
The metabolism of Lenvatinib can be decreased when combined with Curcumin.
Cyclophosphamide
Cyclophosphamide may increase the cardiotoxic activities of Lenvatinib.
Cyclophosphamide Anhydrous
Cyclophosphamide may increase the cardiotoxic activities of Lenvatinib.
Cyclosporine
The metabolism of Lenvatinib can be decreased when combined with Cyclosporine.
Dabrafenib
The serum concentration of Lenvatinib can be decreased when it is combined with Dabrafenib.
Darunavir
The metabolism of Lenvatinib can be decreased when combined with Darunavir.
Dasatinib
The serum concentration of Lenvatinib can be increased when it is combined with Dasatinib.
Dasatinib Anhydrous
The serum concentration of Lenvatinib can be increased when it is combined with Dasatinib.
Deferasirox
The serum concentration of Lenvatinib can be decreased when it is combined with Deferasirox.
Degarelix
Degarelix may increase the QTc-prolonging activities of Lenvatinib.
Delavirdine
The metabolism of Lenvatinib can be decreased when combined with Delavirdine.
Desflurane
Desflurane may increase the QTc-prolonging activities of Lenvatinib.
Desipramine
Desipramine may increase the QTc-prolonging activities of Lenvatinib.
Deslanoside
Deslanoside may decrease the cardiotoxic activities of Lenvatinib.
Digitoxin
Digitoxin may decrease the cardiotoxic activities of Lenvatinib.
Digoxin
Digoxin may decrease the cardiotoxic activities of Lenvatinib.
Dihydroergotamine
The metabolism of Lenvatinib can be decreased when combined with Dihydroergotamine.
Diltiazem
The metabolism of Lenvatinib can be decreased when combined with Diltiazem.
Diphenhydramine
Diphenhydramine may increase the QTc-prolonging activities of Lenvatinib.
Disopyramide
Lenvatinib may increase the QTc-prolonging activities of Disopyramide.
Docetaxel
The risk or severity of adverse effects can be increased when Docetaxel is combined with Lenvatinib.
DOCETAXEL ANHYDROUS
The risk or severity of adverse effects can be increased when Docetaxel is combined with Lenvatinib.
Dofetilide
Lenvatinib may increase the QTc-prolonging activities of Dofetilide.
Dolasetron
Dolasetron may increase the QTc-prolonging activities of Lenvatinib.
Domperidone
Lenvatinib may increase the QTc-prolonging activities of Domperidone.
Doxepin
Doxepin may increase the QTc-prolonging activities of Lenvatinib.
Doxycycline
The metabolism of Lenvatinib can be decreased when combined with Doxycycline.
Doxycycline Anhydrous
The metabolism of Lenvatinib can be decreased when combined with Doxycycline.
Dronedarone
Lenvatinib may increase the QTc-prolonging activities of Dronedarone.
Droperidol
Droperidol may increase the QTc-prolonging activities of Lenvatinib.
Eliglustat
Lenvatinib may increase the QTc-prolonging activities of Eliglustat.
Eltrombopag
The serum concentration of Lenvatinib can be increased when it is combined with Eltrombopag.
Enzalutamide
The serum concentration of Lenvatinib can be decreased when it is combined with Enzalutamide.
Eribulin
Eribulin may increase the QTc-prolonging activities of Lenvatinib.
Erythromycin
Erythromycin may increase the QTc-prolonging activities of Lenvatinib.
Escitalopram
Lenvatinib may increase the QTc-prolonging activities of Escitalopram.
Ezogabine
Ezogabine may increase the QTc-prolonging activities of Lenvatinib.
Famotidine
Famotidine may increase the QTc-prolonging activities of Lenvatinib.
Felbamate
Felbamate may increase the QTc-prolonging activities of Lenvatinib.
Fingolimod
Fingolimod may increase the QTc-prolonging activities of Lenvatinib.
Flecainide
Flecainide may increase the QTc-prolonging activities of Lenvatinib.
Fluconazole
The metabolism of Lenvatinib can be decreased when combined with Fluconazole.
Fluoxetine
Lenvatinib may increase the QTc-prolonging activities of Fluoxetine.
Flupenthixol
Lenvatinib may increase the QTc-prolonging activities of Flupentixol.
Fluvoxamine
The metabolism of Lenvatinib can be decreased when combined with Fluvoxamine.
Formoterol
Formoterol may increase the QTc-prolonging activities of Lenvatinib.
Fosamprenavir
The metabolism of Lenvatinib can be decreased when combined with Fosamprenavir.
Fosaprepitant
The serum concentration of Lenvatinib can be increased when it is combined with Fosaprepitant.
Foscarnet
Foscarnet may increase the QTc-prolonging activities of Lenvatinib.
Fosphenytoin
The metabolism of Lenvatinib can be increased when combined with Fosphenytoin.
Fusidate
The serum concentration of Lenvatinib can be increased when it is combined with Fusidic Acid.
Fusidic Acid
The serum concentration of Lenvatinib can be increased when it is combined with Fusidic Acid.
Gadobenate
Gadobenic acid may increase the QTc-prolonging activities of Lenvatinib.
Galantamine
Galantamine may increase the QTc-prolonging activities of Lenvatinib.
Gemifloxacin
Gemifloxacin may increase the QTc-prolonging activities of Lenvatinib.
Gemifloxacin Mesylate
Gemifloxacin may increase the QTc-prolonging activities of Lenvatinib.
Goserelin
Goserelin may increase the QTc-prolonging activities of Lenvatinib.
Granisetron
Granisetron may increase the QTc-prolonging activities of Lenvatinib.
Haloperidol
Haloperidol may increase the QTc-prolonging activities of Lenvatinib.
Histrelin
Histrelin may increase the QTc-prolonging activities of Lenvatinib.
Hydroxyzine
Hydroxyzine may increase the QTc-prolonging activities of Lenvatinib.
Hypoxis hemerocallidea root extract
The serum concentration of Lenvatinib can be decreased when it is combined with St. John's Wort.
Ibandronate
Ibandronate may increase the QTc-prolonging activities of Lenvatinib.
Ibandronic Acid
Ibandronate may increase the QTc-prolonging activities of Lenvatinib.
Ibutilide
Lenvatinib may increase the QTc-prolonging activities of Ibutilide.
Idelalisib
The metabolism of Lenvatinib can be decreased when combined with Idelalisib.
Iloperidone
Lenvatinib may increase the QTc-prolonging activities of Iloperidone.
Imatinib
The metabolism of Lenvatinib can be decreased when combined with Imatinib.
Imipramine
Imipramine may increase the QTc-prolonging activities of Lenvatinib.
Indacaterol
Indacaterol may increase the QTc-prolonging activities of Lenvatinib.
Indapamide
Indapamide may increase the QTc-prolonging activities of Lenvatinib.
Indinavir
The metabolism of Lenvatinib can be decreased when combined with Indinavir.
INDINAVIR ANHYDROUS
The metabolism of Lenvatinib can be decreased when combined with Indinavir.
Isavuconazole
The serum concentration of Lenvatinib can be increased when it is combined with Isavuconazole.
Isavuconazonium
The metabolism of Lenvatinib can be decreased when combined with Isavuconazonium.
Isoflurane
Isoflurane may increase the QTc-prolonging activities of Lenvatinib.
Isradipine
The metabolism of Lenvatinib can be decreased when combined with Isradipine.
Itraconazole
The metabolism of Lenvatinib can be decreased when combined with Itraconazole.
Ivabradine
Ivabradine may increase the QTc-prolonging activities of Lenvatinib.
Ivacaftor
The serum concentration of Lenvatinib can be increased when it is combined with Ivacaftor.
Ketoconazole
The metabolism of Lenvatinib can be decreased when combined with Ketoconazole.
Lapatinib
Lapatinib may increase the QTc-prolonging activities of Lenvatinib.
Leuprolide
Leuprolide may increase the QTc-prolonging activities of Lenvatinib.
Levofloxacin
Levofloxacin may increase the QTc-prolonging activities of Lenvatinib.
Levofloxacin Anhydrous
Levofloxacin may increase the QTc-prolonging activities of Lenvatinib.
Lithium
Lithium may increase the QTc-prolonging activities of Lenvatinib.
Lithium Cation
Lithium may increase the QTc-prolonging activities of Lenvatinib.
Lopinavir
Lenvatinib may increase the QTc-prolonging activities of Lopinavir.
Lovastatin
The metabolism of Lenvatinib can be decreased when combined with Lovastatin.
Luliconazole
The serum concentration of Lenvatinib can be increased when it is combined with Luliconazole.
Lumacaftor
The serum concentration of Lenvatinib can be decreased when it is combined with Lumacaftor.
Lumefantrine
Lenvatinib may increase the QTc-prolonging activities of Lumefantrine.
Maprotiline
Maprotiline may increase the QTc-prolonging activities of Lenvatinib.
Mefloquine
Mefloquine may increase the QTc-prolonging activities of Lenvatinib.
Methadone
Methadone may increase the QTc-prolonging activities of Lenvatinib.
Methotrimeprazine
Methotrimeprazine may increase the QTc-prolonging activities of Lenvatinib.
Metoclopramide
Metoclopramide may increase the QTc-prolonging activities of Lenvatinib.
Metronidazole
Metronidazole may increase the QTc-prolonging activities of Lenvatinib.
Mifepristone
Mifepristone may increase the QTc-prolonging activities of Lenvatinib.
Mirabegron
Mirabegron may increase the QTc-prolonging activities of Lenvatinib.
Mirtazapine
Mirtazapine may increase the QTc-prolonging activities of Lenvatinib.
Mitotane
The serum concentration of Lenvatinib can be decreased when it is combined with Mitotane.
Moexipril
Moexipril may increase the QTc-prolonging activities of Lenvatinib.
Moxifloxacin
Moxifloxacin may increase the QTc-prolonging activities of Lenvatinib.
Nefazodone
The metabolism of Lenvatinib can be decreased when combined with Nefazodone.
Nelfinavir
The metabolism of Lenvatinib can be decreased when combined with Nelfinavir.
Netupitant
The serum concentration of Lenvatinib can be increased when it is combined with Netupitant.
Nevirapine
The metabolism of Lenvatinib can be increased when combined with Nevirapine.
Nicardipine
Nicardipine may increase the QTc-prolonging activities of Lenvatinib.
Nilotinib
Lenvatinib may increase the QTc-prolonging activities of Nilotinib.
Norfloxacin
Norfloxacin may increase the QTc-prolonging activities of Lenvatinib.
Nortriptyline
Nortriptyline may increase the QTc-prolonging activities of Lenvatinib.
Octreotide
Octreotide may increase the QTc-prolonging activities of Lenvatinib.
Ofloxacin
Ofloxacin may increase the QTc-prolonging activities of Lenvatinib.
Olanzapine
Olanzapine may increase the QTc-prolonging activities of Lenvatinib.
Olaparib
The metabolism of Lenvatinib can be decreased when combined with Olaparib.
Olodaterol
Olodaterol may increase the QTc-prolonging activities of Lenvatinib.
Ondansetron
Ondansetron may increase the QTc-prolonging activities of Lenvatinib.
Osimertinib
The serum concentration of Lenvatinib can be increased when it is combined with Osimertinib.
Ouabain
Ouabain may decrease the cardiotoxic activities of Lenvatinib.
Ovine Digoxin Immune Fab
Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Lenvatinib.
Oxytocin
Oxytocin may increase the QTc-prolonging activities of Lenvatinib.
Paclitaxel
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Lenvatinib.
Palbociclib
The serum concentration of Lenvatinib can be increased when it is combined with Palbociclib.
Paliperidone
Lenvatinib may increase the QTc-prolonging activities of Paliperidone.
Panobinostat
Panobinostat may increase the QTc-prolonging activities of Lenvatinib.
Paroxetine
Paroxetine may increase the QTc-prolonging activities of Lenvatinib.
Pasireotide
Pasireotide may increase the QTc-prolonging activities of Lenvatinib.
Pazopanib
Pazopanib may increase the QTc-prolonging activities of Lenvatinib.
Pentamidine
Pentamidine may increase the QTc-prolonging activities of Lenvatinib.
Pentobarbital
The metabolism of Lenvatinib can be increased when combined with Pentobarbital.
Perflutren
Perflutren may increase the QTc-prolonging activities of Lenvatinib.
Phenobarbital
The metabolism of Lenvatinib can be increased when combined with Phenobarbital.
Phenytoin
The metabolism of Lenvatinib can be increased when combined with Phenytoin.
Pimozide
Lenvatinib may increase the QTc-prolonging activities of Pimozide.
Posaconazole
The metabolism of Lenvatinib can be decreased when combined with Posaconazole.
Primaquine
Primaquine may increase the QTc-prolonging activities of Lenvatinib.
Primidone
The metabolism of Lenvatinib can be increased when combined with Primidone.
Procainamide
Lenvatinib may increase the QTc-prolonging activities of Procainamide.
Promazine
Promazine may increase the QTc-prolonging activities of Lenvatinib.
Promethazine
Promethazine may increase the QTc-prolonging activities of Lenvatinib.
Propafenone
Propafenone may increase the QTc-prolonging activities of Lenvatinib.
Propofol
Propofol may increase the QTc-prolonging activities of Lenvatinib.
Proscillaridin
Proscillaridin may decrease the cardiotoxic activities of Lenvatinib.
Protriptyline
Protriptyline may increase the QTc-prolonging activities of Lenvatinib.
Quetiapine
Lenvatinib may increase the QTc-prolonging activities of Quetiapine.
Quetiapine fumarate
Lenvatinib may increase the QTc-prolonging activities of Quetiapine.
Quinidine
Lenvatinib may increase the QTc-prolonging activities of Quinidine.
Quinine
Lenvatinib may increase the QTc-prolonging activities of Quinine.
Ranolazine
The serum concentration of Lenvatinib can be increased when it is combined with Ranolazine.
Rifabutin
The metabolism of Lenvatinib can be increased when combined with Rifabutin.
Rifampin
The metabolism of Lenvatinib can be increased when combined with Rifampicin.
Rifapentine
The metabolism of Lenvatinib can be increased when combined with Rifapentine.
Rilpivirine
Rilpivirine may increase the QTc-prolonging activities of Lenvatinib.
Risperidone
Risperidone may increase the QTc-prolonging activities of Lenvatinib.
Ritonavir
Ritonavir may increase the QTc-prolonging activities of Lenvatinib.
Rolapitant
The serum concentration of Lenvatinib can be increased when it is combined with Rolapitant.
Rucaparib
The metabolism of Lenvatinib can be decreased when combined with Rucaparib.
Salmeterol
Salmeterol may increase the QTc-prolonging activities of Lenvatinib.
Saquinavir
The metabolism of Lenvatinib can be decreased when combined with Saquinavir.
Saquinavir Mesylate
The metabolism of Lenvatinib can be decreased when combined with Saquinavir.
Sarilumab
The therapeutic efficacy of Lenvatinib can be decreased when used in combination with Sarilumab.
Sertraline
Sertraline may increase the QTc-prolonging activities of Lenvatinib.
Sevoflurane
Sevoflurane may increase the QTc-prolonging activities of Lenvatinib.
Sildenafil
The metabolism of Lenvatinib can be decreased when combined with Sildenafil.
Siltuximab
The serum concentration of Lenvatinib can be decreased when it is combined with Siltuximab.
Simeprevir
The serum concentration of Lenvatinib can be increased when it is combined with Simeprevir.
Solifenacin
Solifenacin may increase the QTc-prolonging activities of Lenvatinib.
Sorafenib
Sorafenib may increase the QTc-prolonging activities of Lenvatinib.
Sotalol
Lenvatinib may increase the QTc-prolonging activities of Sotalol.
ST. JOHN'S WORT EXTRACT
The serum concentration of Lenvatinib can be decreased when it is combined with St. John's Wort.
Sulfamethoxazole
Sulfamethoxazole may increase the QTc-prolonging activities of Lenvatinib.
Sulfisoxazole
Sulfisoxazole may increase the QTc-prolonging activities of Lenvatinib.
Sunitinib
Sunitinib may increase the QTc-prolonging activities of Lenvatinib.
Tamoxifen
Tamoxifen may increase the QTc-prolonging activities of Lenvatinib.
Telaprevir
The metabolism of Lenvatinib can be decreased when combined with Telaprevir.
Telavancin
Telavancin may increase the QTc-prolonging activities of Lenvatinib.
Telithromycin
The metabolism of Lenvatinib can be decreased when combined with Telithromycin.
Terbutaline
Terbutaline may increase the QTc-prolonging activities of Lenvatinib.
Terbutaline Sulfate
Terbutaline may increase the QTc-prolonging activities of Lenvatinib.
Teriflunomide
The serum concentration of Lenvatinib can be increased when it is combined with Teriflunomide.
Tetrabenazine
Lenvatinib may increase the QTc-prolonging activities of Tetrabenazine.
Thioridazine
Lenvatinib may increase the QTc-prolonging activities of Thioridazine.
Thiothixene
Thiothixene may increase the QTc-prolonging activities of Lenvatinib.
Ticlopidine
The metabolism of Lenvatinib can be decreased when combined with Ticlopidine.
Tizanidine
Tizanidine may increase the QTc-prolonging activities of Lenvatinib.
Tocilizumab
The serum concentration of Lenvatinib can be decreased when it is combined with Tocilizumab.
Tolterodine
Tolterodine may increase the QTc-prolonging activities of Lenvatinib.
Toremifene
Lenvatinib may increase the QTc-prolonging activities of Toremifene.
Trastuzumab
Trastuzumab may increase the cardiotoxic activities of Lenvatinib.
Trazodone
Trazodone may increase the QTc-prolonging activities of Lenvatinib.
Treprostinil
Treprostinil may increase the QTc-prolonging activities of Lenvatinib.
Trimethoprim
Trimethoprim may increase the QTc-prolonging activities of Lenvatinib.
Trimipramine
Trimipramine may increase the QTc-prolonging activities of Lenvatinib.
Triptorelin
Triptorelin may increase the QTc-prolonging activities of Lenvatinib.
Vandetanib
Lenvatinib may increase the QTc-prolonging activities of Vandetanib.
Vardenafil
Vardenafil may increase the QTc-prolonging activities of Lenvatinib.
Vemurafenib
The serum concentration of Lenvatinib can be increased when it is combined with Vemurafenib.
Venlafaxine
The metabolism of Lenvatinib can be decreased when combined with Venlafaxine.
Verapamil
The metabolism of Lenvatinib can be decreased when combined with Verapamil.
Vilanterol
Vilanterol may increase the QTc-prolonging activities of Lenvatinib.
Voriconazole
The metabolism of Lenvatinib can be decreased when combined with Voriconazole.
Vorinostat
Vorinostat may increase the QTc-prolonging activities of Lenvatinib.
Ziprasidone
Lenvatinib may increase the QTc-prolonging activities of Ziprasidone.
Zuclopenthixol
Lenvatinib may increase the QTc-prolonging activities of Zuclopenthixol.
